NOACs. Why do we need reversal agents – Harry Buller
Harry Buller
Dept. of Vascular Medicine
Academic Medical Center
Amsterdan
Veja aqui a apresentação completa
novidades científicas
Novo
- 16:13 European Cardiovascular Disease Statistics 2017
- 10:47 CETP inhibitor meets primary endpoint in CV outcome study
- 9:54 Arrhythmias and devices
- 14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
- 14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
